freeze-thaw comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
=== Congress === In response to the investigation announcement, Republican U.S. Senator Thom Tillis, who sits on the Senate Banking Committee, announced that he would oppose any Federal Reserve nomination (including for the vacancy of Powell's seat as chair in May 2026) until the legal matter was resolved, stating: "If there were any remaining doubt whether advisers within the Trump Administration are actively pushing to end the independence of the Federal Reserve, there should now be none. It is now the independence and credibility of the Department of Justice that are in question". Tillis subsequently suggested that he would not support the nomination of National Economic Council Director Kevin Hassett as Federal Reserve Chair to succeed Powell in light of Hassett's past relationship with Trump. Hassett has stated that he is not involved in the investigation, but has stated that he supports it even though he does not expect findings of wrongdoing. Trump later made comments suggesting he would not appoint Hassett to replace Powell, leading to speculation that former Federal Reserve Governor Kevin Warsh had become the leading candidate rather than Hassett, current Federal Reserve Governor Christopher Waller, or Governor Michelle Bowman. Republican Senator Lisa Murkowski supported Tillis' proposal to block all Federal Reserve nominations in response to the investigation, while Susan Collins expressed concern that the investigation was launched in response to White House demands on the central bank's interest rate decisions.
==== Stable isotope labeling with amino acids in cell culture ==== Stable isotope labeling with amino acids in cell culture (SILAC) is a method that involves metabolic incorporation of "heavy" C- or N-labeled amino acids into proteins followed by MS analysis. SILAC requires growing cells in specialized media supplemented with light or heavy forms of essential amino acids, lysine or arginine. One cell population is grown in media containing light amino acids while the experimental condition is grown in the presence of heavy amino acids. The heavy and light amino acids are incorporated into proteins through cellular protein synthesis. Following cell lysis, equal amounts of protein from both conditions are combined and subjected to proteotypic digestion. Arginine and lysine amino acids were chosen, because trypsin, the predominant enzyme used to generate proteotypic peptides for MS analysis, cleaves at the C-terminus of lysine and arginine. Following digestion with trypsin, all the tryptic peptides from cells grown in SILAC media would have at least one labeled amino acid, resulting in a constant mass shift from the labeled sample over non-labeled. Because the peptides containing heavy and light amino acids are chemically identical, they co-elute during reverse-phase column fractionation and are detected simultaneously during MS analysis. The relative protein abundance is determined by the relative peak intensities of the isotopically distinct peptides. Traditionally the level of multiplexing in SILAC was limited due to the number of SILAC isotopes available.
== The influence of age: age-structured models == Age has a deep influence on the disease spread rate in a population, especially the contact rate. This rate summarizes the effectiveness of contacts between susceptible and infectious subjects. Taking into account the ages of the epidemic classes
Sources: en.wikipedia.org
Sumner (1887–1955), 1946 Nobel Prize in Chemistry Kenneth S. Suslick (born 1952), professor at the University of Illinois at Urbana–Champaign, known for optoelectronic nose Edwin Sutermeister (1876–1958), American chemist, known for its work on papermaking Theodor Svedberg (1884–1971), 1926 Nobel Prize in Chemistry Joseph Swan (1828–1914), English physicist, chemist and inventor Frédéric Swarts (1866–1940), Belgian chemist, prepared the first chlorofluorocarbon compound Richard Laurence Millington Synge (1914–1994), 1952 Nobel Prize in Chemistry
Nanoparticles are classified as having at least one of its dimensions in the range of 1-100 nanometers (nm). The small size of nanoparticles allows them to have unique characteristics which may not be possible on the macro-scale. Self-assembly is the spontaneous organization of smaller subunits to form larger, well-organized patterns. For nanoparticles, this spontaneous assembly is a consequence of interactions between the particles aimed at achieving a thermodynamic equilibrium and reducing the system's free energy. The thermodynamics definition of self-assembly was introduced by Professor Nicholas A. Kotov. He describes self-assembly as a process where components of the system acquire non-random spatial distribution with respect to each other and the boundaries of the system. This definition allows one to account for mass and energy fluxes taking place in the self-assembly processes. This process occurs at all size scales, in the form of either static or dynamic self-assembly. Static self-assembly utilizes interactions amongst the nano-particles to achieve a free-energy minimum. In solutions, it is an outcome of random motion of particles and the affinity of their binding sites for one another. A dynamic system is forced to not reach equilibrium by supplying the system with a continuous, external source of energy to balance attractive and repulsive forces. Magnetic fields, electric fields, ultrasound fields, light fields, etc. have all been used as external energy sources to program robot swarms at small scales.
Graham Stuart, MP for Beverley and Holderness, resigns from his ministerial post of Energy Minister with the UK government to spend more time focusing on local issues. He is replaced by Justin Tomlinson. Bambos Charalambous, MP for Enfield Southgate, is readmitted to the Labour Party following a ten month long internal investigation. 13 April – Tim Loughton, MP for East Worthing and Shoreham since 1997, announces he will stand down from parliament at the next election. He becomes the 100th MP to announce they will not seek re-election at the next election. An OpenDemocracy investigation reveals high level Labour politicians met with financial services firms following a £150,000 donation to the party from one of the companies. Simon Geraghty, the former leader of Worcester City Council, announces he will stand down at the May election after 24 years. Leader of Norfolk County Council Kay Mason Billig says that Natural England is blocking the proposed Norwich Northern Distributor Road scheme by protecting a bat colony. Mayor of London Sadiq Khan launches what he describes as a "new climate action plan" for London, which includes a Net Zero Schools target and recommitting to making London Net Zero by 2030. 14 April – Some Conservative MPs and businesspeople are proposing to boycott Downing Street's Eid celebration, scheduled for the following day, because of the UK government's support for Israel. 15 April – Peers living outside London become eligible to claim £100 for accommodation expenses when they attend sittings at the House of Lords.
First explicitly noted in the 19th century by Claude Bernard who named it. Hormone a chemical released by one of the endocrine glands or tissues, and which has effects on other tissues. Insulin is a hormone as are glucagon, adrenaline, and angiotensin II. Human insulin Man-made insulins that is identical to the insulin produced by your own body. It is produced by bacteria which have had insulin genes installed into them. Human insulin has been available since October 1982. Genentech developed the first production mechanism. Hyperglycemia a condition in which glucose levels are higher than usual. Hyperinsulinism Too high a level of insulin in the blood. This often involves a condition in which the body produces too much insulin. Researchers believe that this condition may play a role in the development of noninsulin-dependent diabetes (or perhaps its side-effects) and in hypertension. See also: Syndrome X. Hyperlipemia See: Hyperlipidemia. Hyperlipidemia Too high a level of fats (lipids) in the blood. See also: Syndrome X. Hyperosmolar coma A coma (loss of consciousness) related to high levels of glucose (sugar) in the blood and requiring emergency treatment. A person with this condition is usually older and weak from loss of body fluids and weight. The person may or may not have a previous history of diabetes. Ketones (acids) are not typically present in the urine. Hypertension a condition in which blood pressure is higher than normal. See high blood pressure. Hypoglycemia a condition in which blood glucose levels are lower than normal.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.